Primary Brain Tumor Clinical Trial
Official title:
Computerized Cognitive Training for Childhood Cancer Survivors: A Pilot Study
Verified date | May 2013 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Specific Aim 1: To assess the feasibility and acceptability of a home-based, computerized
attention training program with survivors of central nervous system (CNS) impacting
pediatric cancer (e.g. acute lymphocyte leukemia [ALL], brain tumors).
Specific Aim 2: To estimate the effect size of this attention training program with
survivors of childhood cancer to determine whether a larger-scale clinical trial is
warranted.
Status | Terminated |
Enrollment | 9 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 9 Years to 17 Years |
Eligibility |
Inclusion Criteria: 1. A T-score greater than the 75th percentile on either the Cognitive Problems/Inattention or the DSM-IV Inattention subscales of the Conners' Parent Rating Scale 2. One or more standard deviations below the mean on the Working Memory Index of the WISC-IV or a Working Memory Index that is one or more standard deviations below the participant's estimated IQ. These criteria are based on the eligibility criteria used in the largest trial to date of psychostimulant methylphenidate (MPH; commonly known as Ritalin) with survivors of childhood cancer. Exclusion Criteria: 1. Estimated IQ = 70 2. Motor, visual, or auditory handicap that prevents computer use 3. A diagnosis of attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), depression, autism, or pervasive developmental disorder (PDD) 4. Insufficient fluency in English. Participants who are currently taking stimulant medications (stable dose for at least 30 days) for attentional difficulties, but who meet inclusion criteria will be allowed to participate. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Duke University Health Systems | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Computer program results | baseline and study completion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05539677 -
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
|
||
Recruiting |
NCT04066465 -
Neurocognitive Function After Proton Therapy in Children and Adolescents
|
||
Completed |
NCT02392078 -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
|
||
Not yet recruiting |
NCT02272452 -
Assistance in Neurosurgery (ExtempoRMN)
|
N/A | |
Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
Completed |
NCT02338037 -
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
|
Early Phase 1 | |
Completed |
NCT05328739 -
The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers
|
N/A | |
Completed |
NCT02034708 -
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
|
Phase 4 | |
Completed |
NCT04919993 -
CBT for Insomnia in Primary Brain Tumor Patients
|
N/A | |
Completed |
NCT04075370 -
Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
|
||
Completed |
NCT01242566 -
Temozolomide in Elderly Patients With KPS < 70
|
Phase 2 | |
Not yet recruiting |
NCT06439420 -
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
|
Phase 2 | |
Recruiting |
NCT01535430 -
Assessment of Eloquent Function in Brain Tumor Patients
|
||
Completed |
NCT00285324 -
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
|
N/A | |
Recruiting |
NCT03684109 -
Non-invasive Glioma Characterization Through Molecular Imaging
|
N/A | |
Recruiting |
NCT05576103 -
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
|
||
Not yet recruiting |
NCT00265174 -
Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.
|
N/A | |
Recruiting |
NCT05106296 -
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
|
Phase 1 | |
Completed |
NCT04118426 -
Cognitive Function After Radiation Therapy for Brain Tumours
|
||
Recruiting |
NCT02693405 -
Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life
|
N/A |